Arca
Skip to content
Tools
Tools

Cyclophosphamide: Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See NDA 210852's history or Dr. Reddy's Laboratories's company page.

On Jul 24, 2018, FDA declined to approve Cyclophosphamide (NDA 210852) from Dr. Reddy’s Laboratories, Inc in its present form, citing facility inspections. The application was later approved.

  • Letter date: Jul 24, 2018
  • Application: NDA 210852
  • Since then: Approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Facility inspections

The Letter

Text from openFDA; FDA's scanned original (PDF) ↗

Dear Dr. Rao:

Please refer to your New Drug Application (NDA) dated September 28, 2017, received September 28, 2017, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Cyclophosphamide Injection, 500 mg/mL, | gm/2mL and 2 gm/4mL.

We have completed our review of this application, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

FACILITY INSPECTIONS

During a recent inspection of the Dr. Reddy’s Laboratories Limited (FEI 3006549835) manufacturing facility for this application, our field investigator conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before this application may be approved.

PRESCRIBING INFORMATION

We reserve comment on the proposed labeling until the application is otherwise adequate. Upon resubmission of your application, you must submit a revised proposed label. We encourage you to review the labeling review resources on the PLR Requirements for Prescribing Information and Pregnancy and Lactation Labeling Final Rule websites, including regulations and related guidance documents and the Selected Requirements for Prescribing Information (SRPI) — a checklist of important format items from labeling regulations and guidances.

For your revised labeling, use the SRPI checklist to ensure that the prescribing information conforms with format items in regulations and guidances. Your response must include updated content of labeling [21 CFR 314.50(1)(1)(i)] in structured product labeling (SPL) format as described at http://www. fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm.

CARTON AND CONTAINER LABELING

We reserve comment on the proposed labeling until the application is otherwise adequate. Submit draft carton and container labeling with your resubmission.

SAFETY UPDATE

When you respond to the above deficiencies, include a safety update as described at

21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical and clinical studies/trials of the drug under consideration regardless of indication, dosage form, or dose level.

Describe in detail any significant changes or findings in the safety profile.

When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows:

e Present new safety data from the studies/clinical trials for the proposed indication using the same format as in the original submission.

e Present tabulations of the new safety data combined with the original application data.

e Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies described in the bullet above.

e For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in clinical trials.

Present a retabulation of the reasons for premature trial discontinuation by incorporating the drop-outs from the newly completed trials. Describe any new trends or patterns identified.

Provide case report forms and narrative summaries for each patient who died during a clinical trial or who did not complete a trial because of an adverse event. In addition, provide narrative summaries for serious adverse events.

Describe any information that suggests a substantial change in the incidence of common, ut less serious, adverse events between the new data and the original application data.

Provide updated exposure information for the clinical studies/trials (e.g., number of subjects, person time).

Provide a summary of worldwide experience on the safety of this drug. Include an updated estimate of use for drug marketed in other countries.

Provide English translations of current approved foreign labeling not previously submitted.

OTHER

Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 314.110. If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under 21 CFR 314.65. You may also request an extension of time in which to resubmit the application.

A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "RESUBMISSION" in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle.

You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting, submit your meeting request as described in the draft FDA Guidance for Industry, “Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products,” December 2017 at https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM59054 1.

The drug product may not be legally marketed until you have been notified in writing that this application is approved.

If you have any questions, call Fatima Rizvi, Pharm D, Regulatory Project Manager, at (240) 402-7426.

Sincerely,

{See appended electronic signature page} Amna Ibrahim, MD

Deputy Director

Division of Oncology Products |

Office of Hematology and Oncology Products Center for Drug Evaluation and Research

Signature Page 1 of 1

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

AMNA IBRAHIM

07/24/2018

Other Letters on This Application

Dr. Reddy's Laboratories's Other Letters

Newest first
  • AVT03Dec 30, 2025 · BLA 761471 · not approved
  • DRL_RIOct 16, 2025 · BLA 761376 · not approved
  • BLA 761376Apr 19, 2024 · BLA 761376 · not approved
  • Xeglyze (abametapir) LotionAug 30, 2016 · NDA 206966 · later approved
  • BortezomibMay 4, 2016 · NDA 206927/Original 1, NDA 206927 · later approved
  • BortezomibDec 17, 2014 · NDA 206927/Original 1, NDA 206927 · later approved

Record

Company
Dr. Reddy’s Laboratories, Inc
Application
NDA 210852
Status in openFDA
Approved
Review division
Office of Hematology and Oncology Products

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.